ALLOZYNEs AZ17 antagonist shows positive data for treatment of autoimmune diseases ALLOZYNE Inc.

Unlike almost every other bispecific molecules that are built using genetic fusion, both scFvs that compose AZ17 are conjugated covalently utilizing a synthetic linker. This simultaneous inhibition of two independent Th17 cytokines represents a novel method of treating Th17 linked diseases such as for example multiple sclerosis, Crohn’s and psoriasis.. ALLOZYNE’s AZ17 antagonist shows positive data for treatment of autoimmune diseases ALLOZYNE Inc. Announced today positive data from preclinical research analyzing AZ17 which really is a novel bispecific Th17 antagonist that inhibits the differentiation and effector function of human Th17 cells in vivo.‘Achilles back heel’ in metabolic pathway could stop growth of lung tumor cells Researchers at UT Southwestern INFIRMARY have found an Achilles heel in a metabolic pathway crucial to stopping the growth of lung tumor cells. Ralf Kittler, Assistant Professor in the Eugene McDermott Center for Individual Development and Growth, the Division of Pharmacology, the Harold C. Simmons Cancer Center and the Cecil H. And Ida Green Center for Reproductive Biology Sciences at UT Southwestern.